- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05464784
MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia
September 27, 2023 updated by: MediciNova
A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of MN-001 in Patients Diagnosed With Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia
The design of the Phase 2 clinical trial includes the following elements:
- Multi-center, two-arm, randomized, double-blind, placebo-controlled trial to evaluate MN-001 (tipelukast) vs. placebo in approximately 40 patients in the U.S.
- Patients will be randomized 1:1 to receive either 500 mg/day of MN-001 (tipelukast) or placebo for 24 weeks.
- The co-primary endpoints are (1) change from baseline in liver fat content measured by controlled attenuation parameter (CAP) score at Week 24, and (2) change from baseline in fasting serum triglycerides at Week 24. FebroScan is a non-invasive, quantitative, and accurate measure of liver fat content commonly used in early phase trials to measure treatment response.
- Secondary endpoints include safety and tolerability and changes in lipid profile (HDL-C, LDL-C, and total cholesterol).
Study Overview
Status
Recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
40
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Matsuda
- Phone Number: (858) 373-1500
- Email: clinicaltrialinfo@medicinova.com
Study Locations
-
-
Nevada
-
Las Vegas, Nevada, United States, 89106
- Recruiting
- Jubilee Clinical Research, Inc.
-
Contact:
- Matthew O'Sullivan, M.A.
- Phone Number: 702-631-5000
- Email: mosullivan@jcr-lv.com
-
Principal Investigator:
- Elliott Shin, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- FibroScan® CAP score ≥ 248 dB/m within 8 weeks of randomization.
- Diagnosis or history of Type 2 Diabetes mellitus with hemoglobin A1c (HbA1c) >6.5 and ≤10% at Screening.
- Fasting serum triglycerides (TG) at Screening >150 mg/dL
- On a stable dose of oral antidiabetic therapy for a minimum of 3 months prior to Screening.
Exclusion Criteria:
- Other causes of chronic liver disease (autoimmune, primary biliary cholangitis, HBV, HCV, Wilson's, α-1-antitrypsin deficiency, hemochromatosis, biopsy-proven cirrhosis, hepatocellular carcinoma);
- Documented history of advanced liver fibrosis
- Evidence of cirrhosis, hepatic decompensation, portal hypertension including splenomegaly, ascites, encephalopathy and/or esophageal varices;
- Diagnosis or history of Diabetes mellitus type 1;
- Weight change >5% within last 3 months of Screening visit;
- Active gastrointestinal disease or history of gastric bypass surgery which could interfere with the absorption of oral medication;
- History of clinically significant acute cardiac event within 6 months of Screening;
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MN-001
|
MN-001 is a novel, orally bioavailable small molecule compound
|
Placebo Comparator: MN-001 Placebo
The placebo comparator is a tablet identical in appearance to MN-001.
|
The placebo tablet is identical in appearance to the MN-001 tablet, and contains excipients of MN-001.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Mean change in controlled attenuation parameter (CAP) score by sound-based elastography at Week 24
Time Frame: Week 24
|
Week 24
|
Mean change from baseline in fasting serum triglyceride levels at Week 24
Time Frame: Week 24
|
Week 24
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and tolerability of MN-001
Time Frame: Baseline to Week 24
|
Incidence of adverse events, abnormal clinical laboratory results
|
Baseline to Week 24
|
Mean change from baseline in lipids
Time Frame: Baseline to Week 24
|
Changes in lipids (HDL-C, LDL-C, total cholesterol) after MN-001 treatment for 24 weeks
|
Baseline to Week 24
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Kazuko Matsuda, MD PhD MPH, Medicinova Inc
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 22, 2022
Primary Completion (Estimated)
June 30, 2024
Study Completion (Estimated)
December 31, 2024
Study Registration Dates
First Submitted
June 28, 2022
First Submitted That Met QC Criteria
July 15, 2022
First Posted (Actual)
July 19, 2022
Study Record Updates
Last Update Posted (Actual)
September 29, 2023
Last Update Submitted That Met QC Criteria
September 27, 2023
Last Verified
September 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MN-001-NATG-202
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
US Department of Veterans AffairsAmerican Diabetes AssociationCompletedType 2 Diabetes MellitusUnited States
-
Dexa Medica GroupCompletedType-2 Diabetes MellitusIndonesia
-
AstraZenecaRecruiting
Clinical Trials on MN-001
-
MediciNovaCompletedInterstitial CystitisUnited States
-
Reveal Pharmaceuticals Inc.National Cancer Institute (NCI)RecruitingCentral Nervous System (CNS) LesionsUnited States
-
MediciNovaCompletedIdiopathic Pulmonary Fibrosis | IPFUnited States
-
MediciNovaCompletedNon-alcoholic Fatty Liver Disease | Hypercholesterolemia | Hypertriglyceridemia | Non-alcoholic SteatohepatitisUnited States
-
MediciNovaCompletedChronic Obstructive Pulmonary DiseaseUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedHIV Infections | HIV SeronegativityBrazil, Peru, Haiti, Trinidad and Tobago
-
National Cancer Institute (NCI)CompletedAcquired Immunodeficiency Syndrome | HIV InfectionUnited States
-
Hill-RomCompletedMotor Neuron Disease | Cystic Fibrosis | Airway Clearance ImpairmentUnited States
-
MediciNovaCompleted
-
Guangzhou Magpie Pharmaceuticals Co., Ltd.Not yet recruitingPulmonary Arterial Hypertension